109 related articles for article (PubMed ID: 19233910)
1. A multiplex assay for detecting genetic variations in CYP2C9, VKORC1, and GGCX involved in warfarin metabolism.
Rai AJ; Udar N; Saad R; Fleisher M
Clin Chem; 2009 Apr; 55(4):823-6. PubMed ID: 19233910
[TBL] [Abstract][Full Text] [Related]
2. Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients.
Kimura R; Miyashita K; Kokubo Y; Akaiwa Y; Otsubo R; Nagatsuka K; Otsuki T; Okayama A; Minematsu K; Naritomi H; Honda S; Tomoike H; Miyata T
Thromb Res; 2007; 120(2):181-6. PubMed ID: 17049586
[TBL] [Abstract][Full Text] [Related]
3. Rapid single-nucleotide polymorphism detection of cytochrome P450 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genes for the warfarin dose adjustment by the SMart-amplification process version 2.
Aomori T; Yamamoto K; Oguchi-Katayama A; Kawai Y; Ishidao T; Mitani Y; Kogo Y; Lezhava A; Fujita Y; Obayashi K; Nakamura K; Kohnke H; Wadelius M; Ekström L; Skogastierna C; Rane A; Kurabayashi M; Murakami M; Cizdziel PE; Hayashizaki Y; Horiuchi R
Clin Chem; 2009 Apr; 55(4):804-12. PubMed ID: 19181737
[TBL] [Abstract][Full Text] [Related]
4. Genetic determinants of acenocoumarol and phenprocoumon maintenance dose requirements.
Cadamuro J; Dieplinger B; Felder T; Kedenko I; Mueller T; Haltmayer M; Patsch W; Oberkofler H
Eur J Clin Pharmacol; 2010 Mar; 66(3):253-60. PubMed ID: 20020283
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenetics of target genes across the warfarin pharmacological pathway.
Lal S; Jada SR; Xiang X; Lim WT; Lee EJ; Chowbay B
Clin Pharmacokinet; 2006; 45(12):1189-200. PubMed ID: 17112295
[TBL] [Abstract][Full Text] [Related]
6. Copy number variation and warfarin dosing: evaluation of CYP2C9, VKORC1, CYP4F2, GGCX and CALU.
Scott SA; Patel M; Martis S; Lubitz SA; van der Zee S; Yoo C; Edelmann L; Halperin JL; Desnick RJ
Pharmacogenomics; 2012 Feb; 13(3):297-307. PubMed ID: 22188360
[TBL] [Abstract][Full Text] [Related]
7. The influence of sequence variations in factor VII, gamma-glutamyl carboxylase and vitamin K epoxide reductase complex genes on warfarin dose requirement.
Herman D; Peternel P; Stegnar M; Breskvar K; Dolzan V
Thromb Haemost; 2006 May; 95(5):782-7. PubMed ID: 16676068
[TBL] [Abstract][Full Text] [Related]
8. Influence of clinical and genetic factors on warfarin dose requirements among Japanese patients.
Ohno M; Yamamoto A; Ono A; Miura G; Funamoto M; Takemoto Y; Otsu K; Kouno Y; Tanabe T; Masunaga Y; Nonen S; Fujio Y; Azuma J
Eur J Clin Pharmacol; 2009 Nov; 65(11):1097-103. PubMed ID: 19582440
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of combinatorial CYP2C9 and VKORC1 genotypes in Puerto Ricans: implications for warfarin management in Hispanics.
Duconge J; Cadilla CL; Windemuth A; Kocherla M; Gorowski K; Seip RL; Bogaard K; Renta JY; Piovanetti P; D'Agostino D; Santiago-Borrero PJ; Ruaño G
Ethn Dis; 2009; 19(4):390-5. PubMed ID: 20073138
[TBL] [Abstract][Full Text] [Related]
10. Warfarin genotyping in a single PCR reaction for microchip electrophoresis.
Poe BL; Haverstick DM; Landers JP
Clin Chem; 2012 Apr; 58(4):725-31. PubMed ID: 22317799
[TBL] [Abstract][Full Text] [Related]
11. Combined genetic profiles of components and regulators of the vitamin K-dependent gamma-carboxylation system affect individual sensitivity to warfarin.
Vecsler M; Loebstein R; Almog S; Kurnik D; Goldman B; Halkin H; Gak E
Thromb Haemost; 2006 Feb; 95(2):205-11. PubMed ID: 16493479
[TBL] [Abstract][Full Text] [Related]
12. [Impact of five genetic polymorphisms on inter-individual variation in warfarin maintenance dose].
Huang SW; Xiang DK; Wu HL; Chen BL; An BQ; Li GF
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2011 Dec; 28(6):661-5. PubMed ID: 22161100
[TBL] [Abstract][Full Text] [Related]
13. SYBR Green-based real-time PCR assay for detection of VKORC1 and CYP2C9 polymorphisms that modulate warfarin dose requirement.
Huang SW; Li Q; Zhu SY; Li L; Xiong F; Jia YK; Xu XM
Clin Chem Lab Med; 2009; 47(1):26-31. PubMed ID: 19117406
[TBL] [Abstract][Full Text] [Related]
14. Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study.
Carlquist JF; Horne BD; Muhlestein JB; Lappé DL; Whiting BM; Kolek MJ; Clarke JL; James BC; Anderson JL
J Thromb Thrombolysis; 2006 Dec; 22(3):191-7. PubMed ID: 17111199
[TBL] [Abstract][Full Text] [Related]
15. Clinical relevance of VKORC1 (G-1639A and C1173T) and CYP2C9*3 among patients on warfarin.
Teh LK; Langmia IM; Fazleen Haslinda MH; Ngow HA; Roziah MJ; Harun R; Zakaria ZA; Salleh MZ
J Clin Pharm Ther; 2012 Apr; 37(2):232-6. PubMed ID: 21507031
[TBL] [Abstract][Full Text] [Related]
16. [Association between CYP2C9 and VKORC1 genetic polymorphism and warfarin dose requirements].
Yang J; Miao LY; Huang CR; Shen ZY; Jiang WP
Zhonghua Xin Xue Guan Bing Za Zhi; 2008 Feb; 36(2):137-40. PubMed ID: 19099951
[TBL] [Abstract][Full Text] [Related]
17. Common genetic variants of microsomal epoxide hydrolase affect warfarin dose requirements beyond the effect of cytochrome P450 2C9.
Loebstein R; Vecsler M; Kurnik D; Austerweil N; Gak E; Halkin H; Almog S
Clin Pharmacol Ther; 2005 May; 77(5):365-72. PubMed ID: 15900282
[TBL] [Abstract][Full Text] [Related]
18. Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients.
Miao L; Yang J; Huang C; Shen Z
Eur J Clin Pharmacol; 2007 Dec; 63(12):1135-41. PubMed ID: 17899045
[TBL] [Abstract][Full Text] [Related]
19. Building individualized medicine: prevention of adverse reactions to warfarin therapy.
Krynetskiy E; McDonnell P
J Pharmacol Exp Ther; 2007 Aug; 322(2):427-34. PubMed ID: 17496169
[TBL] [Abstract][Full Text] [Related]
20. Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements.
Aquilante CL; Langaee TY; Lopez LM; Yarandi HN; Tromberg JS; Mohuczy D; Gaston KL; Waddell CD; Chirico MJ; Johnson JA
Clin Pharmacol Ther; 2006 Apr; 79(4):291-302. PubMed ID: 16580898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
